Effects of pancrelipase on nonalcoholic fatty liver disease after pancreaticoduodenectomy

Background Postoperative nonalcoholic fatty liver disease (NAFLD) after pancreaticoduodenectomy (PD) has recently become recognized. However, the pathoetiology of postoperative NAFLD is largely unknown. Furthermore, the optimal treatment has not been established. The aim of this prospective study wa...

Full description

Saved in:
Bibliographic Details
Published in:Journal of hepato-biliary-pancreatic sciences 2014-03, Vol.21 (3), p.186-192
Main Authors: Nagai, Minako, Sho, Masayuki, Satoi, Sohei, Toyokawa, Hideyoshi, Akahori, Takahiro, Yanagimoto, Hiroaki, Yamamoto, Tomohisa, Hirooka, Satoshi, Yamaki, So, Kinoshita, Shoichi, Nishiwada, Satoshi, Ikeda, Naoya, Kwon, A-Hon, Nakajima, Yoshiyuki
Format: Article
Language:English
Subjects:
Adult
Aged
Aged, 80 and over
Complication
Female
Gastrointestinal Agents - administration & dosage
Gastrointestinal Agents - therapeutic use
Humans
Liver cirrhosis
Liver diseases
Maldigestion
Male
Middle Aged
NAFLD
Non-alcoholic Fatty Liver Disease - diagnostic imaging
Non-alcoholic Fatty Liver Disease - drug therapy
Nutritional Status
Pancreaticoduodenectomy
Pancreaticoduodenectomy - adverse effects
Pancrelipase
Pancrelipase - administration & dosage
Pancrelipase - therapeutic use
Postoperative Complications - drug therapy
Prospective Studies
Tomography, X-Ray Computed
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background Postoperative nonalcoholic fatty liver disease (NAFLD) after pancreaticoduodenectomy (PD) has recently become recognized. However, the pathoetiology of postoperative NAFLD is largely unknown. Furthermore, the optimal treatment has not been established. The aim of this prospective study was to clarify whether pancrelipase, which contains digestive pancreatic enzymes, could reverse NAFLD. Methods A collaborative clinical trial has been conducted (UMIN000006841). A total of 30 patients who developed NAFLD after PD were prospectively treated with pancrelipase. NAFLD was defined and evaluated by the liver‐to‐spleen attenuation ratio on computed tomography (CT). Clinical symptoms and laboratory findings were also assessed. Results The mean liver‐to‐spleen CT ratio before surgery in 30 patients was 1.233. It declined to 0.453 at diagnosis of NAFLD. It was significantly improved by the treatment and the CT ratios at 1, 3 and 6 months after treatment were 0.762, 0.958 and 0.904, respectively (vs. pretreatment, P 
ISSN:1868-6974
1868-6982
DOI:10.1002/jhbp.14